Prasad Devarajan

7662578, Feb 16, 2010

Apr 19, 2007

11/737326

Prasad Devarajan - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

G01N 33/53
G01N 33/543

435 721, 435 71, 436501, 436518, 422 61

A method and kit for identifying the presence of an early biomarker of impaired renal status following a renal event in a mammalian subject. The method typically comprises (a) providing a body fluid sample obtained from a mammalian subject following a renal event; and (b) detecting in the provided sample the presence of a protein selected from the group consisting of aprotinin, alpha-1-microglobulin (A1M), alpha-1-acid-glycoprotein (A1AG), microalbumin, and combinations thereof, the presence thereof serving as an early biomarker of a change in renal status. The method can include a kit for point-of-care detection of the early biomarker of impaired renal status. Identification of the presence or absence of the early biomarker typically directs a caregiver's therapeutic decision regarding managing treatment of the subject for impaired renal status. The invention also includes a method of assessing the administration of aprotinin during cardiopulmonary bypass surgery and provides for methods where the level of aprotinin in the subject's urine directs a caregiver's therapeutic decision regarding the intra-operative administration of aprotinin.

7776824, Aug 17, 2010

May 6, 2005

11/123364

Jonathan M. Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Kiyoshi Mori - New York NY, US

The Trustees of Columbia University - New York NY
Children's Hospital Medical Center - Cincincati OH

A61K 38/04
A01N 1/00
A01N 1/02

514 12, 435 11

Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.

7977110, Jul 12, 2011

Jun 21, 2008

12/143769

Jonathan Matthew Barasch - New York City NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US

Children's Hospital Medical Center - Cincinnati OH
The Trustees of Columbia University - New York NY

C12Q 1/25
G01N 33/53

436 96, 435 4, 435 79

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

8247376, Aug 21, 2012

Jun 17, 2010

12/817566

Jonathan M. Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Kiyoshi Mori - New York NY, US

The Trustees of Columbia University - New York NY
Children's Hospital Medical Center - Cincinnati OH

A61K 38/00
A61P 13/12

514 154

Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.

8617802, Dec 31, 2013

Sep 26, 2008

12/239158

Jörg Köhl - Cincinnati OH, US
Prasad Devarajan - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

A01N 1/02
A61K 38/16
A61K 38/00
C12M 1/00

435 12, 435 11, 4352831, 4352841, 514 11, 514 213

A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5anaphylatoxin which is a C5receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated.

20040219603, Nov 4, 2004

Mar 26, 2004

10/811130

Prasad Devarajan - Cincinnati OH, US
Jonathan Barasch - New York NY, US

G01N033/53
A61K031/675

435/007100

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

20050272101, Dec 8, 2005

Mar 31, 2005

11/096113

Prasad Devarajan - Cincinnati OH, US
Jonathan Barasch - New York NY, US

G01N033/53
G01N033/542

435007900

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

20070037232, Feb 15, 2007

Oct 13, 2005

11/374285

Jonathan Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kyoto, JP

G01N 33/53

435007920

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.